Logo image of FRLN

FREELINE THERAPEUTICS HOLDIN (FRLN) Stock Fundamental Analysis

NASDAQ:FRLN - US35655L2060 - ADR

6.48 USD
0 (0%)
Last: 2/16/2024, 8:00:24 PM
6.48 USD
0 (0%)
After Hours: 2/16/2024, 8:00:24 PM
Fundamental Rating

2

FRLN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. The financial health of FRLN is average, but there are quite some concerns on its profitability. FRLN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year FRLN has reported negative net income.
FRLN had a negative operating cash flow in the past year.
FRLN had negative earnings in each of the past 5 years.
In the past 5 years FRLN always reported negative operating cash flow.
FRLN Yearly Net Income VS EBIT VS OCF VS FCFFRLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -101.44%, FRLN is doing worse than 79.22% of the companies in the same industry.
FRLN's Return On Equity of -166.21% is on the low side compared to the rest of the industry. FRLN is outperformed by 70.44% of its industry peers.
Industry RankSector Rank
ROA -101.44%
ROE -166.21%
ROIC N/A
ROA(3y)-79.36%
ROA(5y)-79.42%
ROE(3y)-108.32%
ROE(5y)-106.61%
ROIC(3y)N/A
ROIC(5y)N/A
FRLN Yearly ROA, ROE, ROICFRLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FRLN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FRLN Yearly Profit, Operating, Gross MarginsFRLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

FRLN has more shares outstanding than it did 1 year ago.
FRLN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FRLN Yearly Shares OutstandingFRLN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 1M 2M 3M 4M
FRLN Yearly Total Debt VS Total AssetsFRLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -16.64, we must say that FRLN is in the distress zone and has some risk of bankruptcy.
FRLN has a Altman-Z score of -16.64. This is amonst the worse of the industry: FRLN underperforms 88.34% of its industry peers.
FRLN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.64
ROIC/WACCN/A
WACCN/A
FRLN Yearly LT Debt VS Equity VS FCFFRLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

FRLN has a Current Ratio of 1.95. This is a normal value and indicates that FRLN is financially healthy and should not expect problems in meeting its short term obligations.
FRLN has a Current ratio of 1.95. This is amonst the worse of the industry: FRLN underperforms 80.24% of its industry peers.
A Quick Ratio of 1.95 indicates that FRLN should not have too much problems paying its short term obligations.
The Quick ratio of FRLN (1.95) is worse than 78.72% of its industry peers.
Industry RankSector Rank
Current Ratio 1.95
Quick Ratio 1.95
FRLN Yearly Current Assets VS Current LiabilitesFRLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for FRLN have decreased strongly by -49.48% in the last year.
EPS 1Y (TTM)-49.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, FRLN will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.20% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y97.48%
EPS Next 2Y29.2%
EPS Next 3Y28.42%
EPS Next 5Y14.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FRLN Yearly Revenue VS EstimatesFRLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2026 2027 2028 2029 2030 100M 200M 300M
FRLN Yearly EPS VS EstimatesFRLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FRLN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FRLN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FRLN Price Earnings VS Forward Price EarningsFRLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FRLN Per share dataFRLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as FRLN's earnings are expected to grow with 28.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.2%
EPS Next 3Y28.42%

More info and screens

0

5. Dividend

5.1 Amount

FRLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FREELINE THERAPEUTICS HOLDIN

NASDAQ:FRLN (2/16/2024, 8:00:24 PM)

After market: 6.48 0 (0%)

6.48

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2023-11-13/amc
Earnings (Next)02-29 2024-02-29/amc
Inst Owners1.99%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap28.24M
Analysts80
Price Target8.41 (29.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-44.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)90.94%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 45.18
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)-25.95
EYN/A
EPS(NY)-8.58
Fwd EYN/A
FCF(TTM)-15.85
FCFYN/A
OCF(TTM)-14.81
OCFYN/A
SpS0.14
BVpS6.89
TBVpS6.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -101.44%
ROE -166.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.36%
ROA(5y)-79.42%
ROE(3y)-108.32%
ROE(5y)-106.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 313.6%
Cap/Sales 727.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.95
Quick Ratio 1.95
Altman-Z -16.64
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)237.65%
Cap/Depr(5y)259.13%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.62%
EPS Next Y97.48%
EPS Next 2Y29.2%
EPS Next 3Y28.42%
EPS Next 5Y14.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.96%
EBIT Next 3Y29.13%
EBIT Next 5Y17.65%
FCF growth 1Y23.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27%
OCF growth 3YN/A
OCF growth 5YN/A